ASH 2014:动态血压的心血管风险预测价值优于诊室/家庭血压

2014-05-21 国际循环 国际循环

一项最新研究旨在比较诊室血压、家庭血压及动态血压对心血管风险的预测价值。 研究者芬兰国家卫生与福利研究所的Teemu Niiranen等入选464例受试者,测量其诊室血压、家庭血压、24小时动态血压及其他心血管危险因素。研究主要终点是心血管死亡、非致死性心肌梗死、非致死性卒中、因心力衰竭住院、行经皮冠状动脉介入治疗或冠状动脉旁路移植术等心血管事件的复合终点。采用Cox比例风险模型

一项最新研究旨在比较诊室血压、家庭血压及动态血压对心血管风险的预测价值。




研究者芬兰国家卫生与福利研究所的Teemu Niiranen等入选464例受试者,测量其诊室血压、家庭血压、24小时动态血压及其他心血管危险因素。研究主要终点是心血管死亡、非致死性心肌梗死、非致死性卒中、因心力衰竭住院、行经皮冠状动脉介入治疗或冠状动脉旁路移植术等心血管事件的复合终点。采用Cox比例风险模型校正其他心血管危险因素后,评估诊室血压、家庭血压及24小时动态血压对患者预后的独立预测价值。

中位随访16.1±3.9年的结果显示,共计70例(13.9%)受试者发生至少一次心血管事件。诊室血压、家庭血压及24小时动态血压均对心血管事件有预测价值,三种血压的收缩压/舒张压每增加1 mmHg,受试者发生心血管事件复合终点的风险比(HR)分别为1.024/1.018(95%CI:1.009~1.040/0.994~1.043)、1.029/1.028(95%CI:1.013~1.045/1.005~1.052)和1.033/1.049(95%CI:1.019~1.047/1.023~1.077)。发三种血压均被纳入至分析模型时,仅24小时动态收缩压及舒张压是心血管事件的显著预测因素(P=0.002和P<0.001),诊室及家庭血压则对心血管事件并无显著预测价值。

综上可见,动态血压对心血管风险的预测价值显著优于诊室/家庭血压。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2082349, encodeId=eb912082349ad, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Apr 17 12:53:00 CST 2015, time=2015-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301115, encodeId=eb8d1301115b3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485899, encodeId=22bc148589945, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508980, encodeId=12a9150898005, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626457, encodeId=13e9162645ecc, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2082349, encodeId=eb912082349ad, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Apr 17 12:53:00 CST 2015, time=2015-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301115, encodeId=eb8d1301115b3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485899, encodeId=22bc148589945, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508980, encodeId=12a9150898005, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626457, encodeId=13e9162645ecc, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=)]
    2014-05-23 kksonne
  3. [GetPortalCommentsPageByObjectIdResponse(id=2082349, encodeId=eb912082349ad, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Apr 17 12:53:00 CST 2015, time=2015-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301115, encodeId=eb8d1301115b3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485899, encodeId=22bc148589945, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508980, encodeId=12a9150898005, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626457, encodeId=13e9162645ecc, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2082349, encodeId=eb912082349ad, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Apr 17 12:53:00 CST 2015, time=2015-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301115, encodeId=eb8d1301115b3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485899, encodeId=22bc148589945, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508980, encodeId=12a9150898005, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626457, encodeId=13e9162645ecc, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2082349, encodeId=eb912082349ad, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Fri Apr 17 12:53:00 CST 2015, time=2015-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301115, encodeId=eb8d1301115b3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485899, encodeId=22bc148589945, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508980, encodeId=12a9150898005, content=<a href='/topic/show?id=a7c83311e88' target=_blank style='color:#2F92EE;'>#动态血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33117, encryptionId=a7c83311e88, topicName=动态血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1e10025437, createdName=limedical1977, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626457, encodeId=13e9162645ecc, content=<a href='/topic/show?id=558b100221c7' target=_blank style='color:#2F92EE;'>#预测价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100221, encryptionId=558b100221c7, topicName=预测价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5f621038683, createdName=changjitao2016, createdTime=Fri May 23 02:53:00 CST 2014, time=2014-05-23, status=1, ipAttribution=)]

相关资讯

ASH 2014:压力感受性反射激活疗法治疗顽固性高血压持续安全有效

Rheos枢纽试验的延长期研究,旨在评估压力感受性反射激活疗法(BAT)治疗顽固性高血压的长期疗效及安全性。 研究者芝加哥大学医学中心的George Bakris 等人在对322例顽固性高血压患者完成为期12个月的随访及终点数据收集后,继续每两年一次收集其血压及安全性数据。为期至少五年的随访结果显示,共计254例(79%)患者对BAT治疗有反应,其血压持续显著降低(P<0.001)。安全性

ASH 2014:血压访视间变异性增大可增加冠心病、卒中、心力衰竭及全因死亡风险

既往研究显示,血压访视间变异性(VVV)增大会增加特定人群卒中、冠心病(CHD)及全因死亡风险,但其对一般人群上述结局及心力衰竭的影响则尚不确定。 研究者美国阿拉巴马大学伯明翰分校的Paul Muntner等人对降压和降脂治疗预防心脏病发作试验(ALLHAT)的24 004例受试者进行中位4.9年的随访,以评估收缩压及舒张压VVV与致死性CHD、非致死性心肌梗死、全因死亡率、卒中及心力衰竭的相关

ASH 2014:探寻高血压患者中脉搏波速度与HDL-C的相关性

既往研究表明,脉搏波速度(PWV)所测得的动脉僵硬度增加是心血管疾病的独立预测因素,高密度脂蛋白胆固醇(HDL-C)水平降低可增加冠状动脉疾病发生风险。中国一项研究旨在探讨高血压患者中PWV与HDL-C的相关性。 研究者Hongyu Wang等人共计入选542例受试者(男/女:336/206,平均年龄为50.17±12.32岁),将其分为对照组(n=402,男/女:234/168,平均年龄为48

第53届ASH年会 AML临床研究新近进展

  急性髓细胞白血病(AML)是每年美国血液病学会(ASH)年会最主要的部分。2011年ASH年会共有887篇有关AML的论文,其中临床试验方面的论文257篇(口头发言96篇),诊断方面的论文301篇(口头发言78篇),机制研究方面的论文191篇(口头发言65篇)。本文将就AML治疗方面一些主要亮点研究作一分析,介绍给国内医生。   AML化疗方案的优化   AML标准的化疗方案对于55岁以下